Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Pharmacology/Therapy

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations

Lung Cancer | Dec 09, 2020 Pharmacology/Therapy

Pembrolizumab in microsatellite-instability–high advanced colorectal cancer

New England Journal of Medicine | Dec 08, 2020 Pharmacology/Therapy

Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy

Lung Cancer | Dec 08, 2020 Pharmacology/Therapy

Osimertinib is associated with reversible and dose-independent cancer therapy- related cardiac dysfunction

Lung Cancer | Dec 06, 2020 Pharmacology/Therapy

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1–positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

International Journal of Cancer | Dec 02, 2020 Pharmacology/Therapy

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC)

Lung Cancer | Dec 02, 2020 Pharmacology/Therapy

Drug use and cancer risk: A drug-wide association study (DWAS) in Norway

Cancer Epidemiology, Biomarkers & Prevention | Dec 02, 2020 Pharmacology/Therapy

Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression

Lung Cancer | Nov 27, 2020 Pharmacology/Therapy

Nivolumab vs docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lung Cancer | Nov 27, 2020 Pharmacology/Therapy

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Lung Cancer | Nov 25, 2020 Pharmacology/Therapy

« Prev 1 … 58 59 60 61 62 … 375 Next »

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations

Pembrolizumab in microsatellite-instability–high advanced colorectal cancer

Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy

Osimertinib is associated with reversible and dose-independent cancer therapy- related cardiac dysfunction

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1–positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC)

Drug use and cancer risk: A drug-wide association study (DWAS) in Norway

Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression

Nivolumab vs docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Article on Hypertension in CKD Patients: Management Updates

Article: Anti-Inflammatory Diets for Pain and Arthritis Management

Artice: Adult Vaccination Updates Every Family Doctor Should Know

Article: Clinical Guide to Molecular Testing in Bethesda III and IV Nodules for Indian Practice

New research aims to transform treatments of aggressive blood cancer

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations

Pembrolizumab in microsatellite-instability–high advanced colorectal cancer

Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy

Osimertinib is associated with reversible and dose-independent cancer therapy- related cardiac dysfunction

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1–positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC)

Drug use and cancer risk: A drug-wide association study (DWAS) in Norway

Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression

Nivolumab vs docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Article on Hypertension in CKD Patients: Management Updates

Article: Anti-Inflammatory Diets for Pain and Arthritis Management

Artice: Adult Vaccination Updates Every Family Doctor Should Know

Article: Clinical Guide to Molecular Testing in Bethesda III and IV Nodules for Indian Practice

New research aims to transform treatments of aggressive blood cancer

Select Specialty

Select Topic